 |
The Journal of Neuroscience, May 19, 2004, 24(20):4778-4786; doi:10.1523/JNEUROSCI.0808-04.2004
Previous Article | Next Article 
Neurobiology of Disease
Castration Restores Function and Neurofilament Alterations of Aged Symptomatic Males in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy
Erica S. Chevalier-Larsen,1
Christopher J. O'Brien,1
Huiyi Wang,1
Shannon C. Jenkins,1
Latia Holder,1
Andrew P. Lieberman,2 and
Diane E. Merry1
1Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, and 2Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109
Transgenic models of neurodegenerative disease have proved uniquely powerful for delineating pathways of neuronal dysfunction and cell death. We have developed a transgenic model of the polyglutamine disease spinal and bulbar muscular atrophy (SBMA), an adult-onset, slowly progressive motor neuron disease caused by polyglutamine expansion in the androgen receptor (AR). Mice bearing a human AR with 112 glutamines reproduce many aspects of SBMA, including slowly progressive, gender-specific motor deficits, and neuronal intranuclear inclusions. Despite substantial motor deficits in male AR112Q mice, no motor neuron loss was observed, indicating that neuronal dysfunction, rather than neuronal death, is central to disease. Moreover, reduced levels of unphosphorylated neurofilament heavy chain (NF-H) were observed in motor neurons, suggesting a role for NF-H in SBMA neuronal dysfunction. The elimination of androgens by surgical castration of severely affected, aged 112Q male mice partially restored motor function as well as NF-H levels. These data suggest that hormone-based therapies designed to treat SBMA patients, even with advanced disease, are likely to be effective.
Key words: androgen; testosterone; motor neuron; neurofilament; polyglutamine; animal model; neurodegeneration; transgenic
Received Oct 14, 2003;
revised April 9, 2004;
accepted April 9, 2004.
This article has been cited by other articles:

|
 |

|
 |
 
K. Suzuki, M. Katsuno, H. Banno, Y. Takeuchi, N. Atsuta, M. Ito, H. Watanabe, F. Yamashita, N. Hori, T. Nakamura, et al.
CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA
Brain,
January 1, 2008;
131(1):
229 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Monks, J. A. Johansen, K. Mo, P. Rao, B. Eagleson, Z. Yu, A. P. Lieberman, S. M. Breedlove, and C. L. Jordan
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease
PNAS,
November 13, 2007;
104(46):
18259 - 18264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Palazzolo, B. G. Burnett, J. E. Young, P. L. Brenne, A. R. La Spada, K. H. Fischbeck, B. W. Howell, and M. Pennuto
Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity
Hum. Mol. Genet.,
July 1, 2007;
16(13):
1593 - 1603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Adachi, M. Waza, K. Tokui, M. Katsuno, M. Minamiyama, F. Tanaka, M. Doyu, and G. Sobue
CHIP Overexpression Reduces Mutant Androgen Receptor Protein and Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model
J. Neurosci.,
May 9, 2007;
27(19):
5115 - 5126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Li, E. S. Chevalier-Larsen, D. E. Merry, and M. I. Diamond
Soluble Androgen Receptor Oligomers Underlie Pathology in a Mouse Model of Spinobulbar Muscular Atrophy
J. Biol. Chem.,
February 2, 2007;
282(5):
3157 - 3164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Katsuno, H. Adachi, M. Minamiyama, M. Waza, K. Tokui, H. Banno, K. Suzuki, Y. Onoda, F. Tanaka, M. Doyu, et al.
Reversible Disruption of Dynactin 1-Mediated Retrograde Axonal Transport in Polyglutamine-Induced Motor Neuron Degeneration.
J. Neurosci.,
November 22, 2006;
26(47):
12106 - 12117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B Gran, N Tabibzadeh, A Martin, E S Ventura, J H Ware, G-X Zhang, J L Parr, A R Kennedy, and A M Rostami
The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis
Multiple Sclerosis,
November 1, 2006;
12(6):
688 - 697.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Thomas Jr, G. S. Fraley, V. Damien, L. B. Woodke, F. Zapata, B. L. Sopher, S. R. Plymate, and A. R. La Spada
Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy
Hum. Mol. Genet.,
July 15, 2006;
15(14):
2225 - 2238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yu, N. Dadgar, M. Albertelli, A. Scheller, R. L. Albin, D. M. Robins, and A. P. Lieberman
Abnormalities of Germ Cell Maturation and Sertoli Cell Cytoskeleton in Androgen Receptor 113 CAG Knock-In Mice Reveal Toxic Effects of the Mutant Protein
Am. J. Pathol.,
January 1, 2006;
168(1):
195 - 204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Katsuno, C. Sang, H. Adachi, M. Minamiyama, M. Waza, F. Tanaka, M. Doyu, and G. Sobue
Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease
PNAS,
November 15, 2005;
102(46):
16801 - 16806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thomas, Z. Yu, N. Dadgar, S. Varambally, J. Yu, A. M. Chinnaiyan, and A. P. Lieberman
The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor
J. Biol. Chem.,
June 3, 2005;
280(22):
21264 - 21271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Adachi, M. Katsuno, M. Minamiyama, M. Waza, C. Sang, Y. Nakagomi, Y. Kobayashi, F. Tanaka, M. Doyu, A. Inukai, et al.
Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients
Brain,
March 1, 2005;
128(3):
659 - 670.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|